Does the media favor TXG or MTD?

In the previous week, 10x Genomics had 7 more articles in the media than Mettler-Toledo International. MarketBeat recorded 16 mentions for 10x Genomics and 9 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.10 beat 10x Genomics' score of 0.68 indicating that Mettler-Toledo International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mettler-Toledo International 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, TXG or MEDP?

Medpace has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 14.73 -$43.54M -$0.59 N/A Medpace $2.53B 6.80 $451.12M $17.06 36.13

Is TXG or MEDP more profitable?

Medpace has a net margin of 17.67% compared to 10x Genomics' net margin of -12.18%. Medpace's return on equity of 110.15% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -12.18% -9.33% -7.30% Medpace 17.67% 110.15% 24.84%

Does the media prefer TXG or MEDP?

In the previous week, 10x Genomics had 8 more articles in the media than Medpace. MarketBeat recorded 16 mentions for 10x Genomics and 8 mentions for Medpace. Medpace's average media sentiment score of 1.40 beat 10x Genomics' score of 0.68 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, TXG or RVTY?

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 14.73 -$43.54M -$0.59 N/A Revvity $2.86B 5.71 $241.20M $2.10 69.54

Is TXG or RVTY more profitable?

Revvity has a net margin of 8.16% compared to 10x Genomics' net margin of -12.18%. Revvity's return on equity of 8.34% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -12.18% -9.33% -7.30% Revvity 8.16% 8.34% 5.01%

Does the media favor TXG or RVTY?

In the previous week, 10x Genomics had 1 more articles in the media than Revvity. MarketBeat recorded 16 mentions for 10x Genomics and 15 mentions for Revvity. Revvity's average media sentiment score of 0.77 beat 10x Genomics' score of 0.68 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

10x Genomics (TXG) Competitors

$72.68 -1.71 (-2.30%)

Closing price 04:00 PM Eastern

Extended Trading

$72.30 -0.39 (-0.53%)

As of 06:13 PM Eastern

Compare

TXG vs. PACB, MTD, MEDP, RVTY, and CRL

Should you buy 10x Genomics stock or one of its competitors? 10x Genomics's main competitors and comparable companies include Pacific Biosciences of California (PACB), Mettler-Toledo International (MTD), Medpace (MEDP), Revvity (RVTY), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does 10x Genomics compare to Pacific Biosciences of California?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, 10x Genomics had 12 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 16 mentions for 10x Genomics and 4 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.75 beat 10x Genomics' score of 0.68 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	14.73	-$43.54M	-$0.59	N/A
Pacific Biosciences of California	$160.01M	2.60	-$546.38M	-$0.43	N/A

10x Genomics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

10x Genomics has a net margin of -12.18% compared to Pacific Biosciences of California's net margin of -82.49%. 10x Genomics' return on equity of -9.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

10x Genomics presently has a consensus price target of $44.00, indicating a potential downside of 39.46%. Pacific Biosciences of California has a consensus price target of $1.71, indicating a potential upside of 27.80%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

10x Genomics beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Mettler-Toledo International?

10x Genomics (NASDAQ:TXG) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

10x Genomics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

10x Genomics currently has a consensus price target of $44.00, suggesting a potential downside of 39.46%. Mettler-Toledo International has a consensus price target of $1,446.36, suggesting a potential upside of 4.69%. Given Mettler-Toledo International's stronger consensus rating and higher possible upside, analysts clearly believe Mettler-Toledo International is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, 10x Genomics had 7 more articles in the media than Mettler-Toledo International. MarketBeat recorded 16 mentions for 10x Genomics and 9 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.10 beat 10x Genomics' score of 0.68 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mettler-Toledo International	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mettler-Toledo International has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	14.73	-$43.54M	-$0.59	N/A
Mettler-Toledo International	$4.03B	6.88	$869.19M	$44.43	31.09

Mettler-Toledo International has a net margin of 21.91% compared to 10x Genomics' net margin of -12.18%. 10x Genomics' return on equity of -9.33% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

Summary

Mettler-Toledo International beats 10x Genomics on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Medpace?

10x Genomics (NASDAQ:TXG) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Medpace has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	14.73	-$43.54M	-$0.59	N/A
Medpace	$2.53B	6.80	$451.12M	$17.06	36.13

In the previous week, 10x Genomics had 8 more articles in the media than Medpace. MarketBeat recorded 16 mentions for 10x Genomics and 8 mentions for Medpace. Medpace's average media sentiment score of 1.40 beat 10x Genomics' score of 0.68 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

10x Genomics presently has a consensus price target of $44.00, indicating a potential downside of 39.46%. Medpace has a consensus price target of $595.20, indicating a potential downside of 3.45%. Given Medpace's stronger consensus rating and higher probable upside, analysts plainly believe Medpace is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

10x Genomics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Medpace has a net margin of 17.67% compared to 10x Genomics' net margin of -12.18%. Medpace's return on equity of 110.15% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats 10x Genomics on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Revvity?

10x Genomics (NASDAQ:TXG) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Revvity has a net margin of 8.16% compared to 10x Genomics' net margin of -12.18%. Revvity's return on equity of 8.34% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Revvity	8.16%	8.34%	5.01%

In the previous week, 10x Genomics had 1 more articles in the media than Revvity. MarketBeat recorded 16 mentions for 10x Genomics and 15 mentions for Revvity. Revvity's average media sentiment score of 0.77 beat 10x Genomics' score of 0.68 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics presently has a consensus price target of $44.00, suggesting a potential downside of 39.46%. Revvity has a consensus price target of $116.57, suggesting a potential downside of 20.18%. Given Revvity's higher possible upside, analysts clearly believe Revvity is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

10x Genomics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Revvity has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	14.73	-$43.54M	-$0.59	N/A
Revvity	$2.86B	5.71	$241.20M	$2.10	69.54

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 0.9% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Revvity beats 10x Genomics on 10 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Charles River Laboratories International?

10x Genomics (NASDAQ:TXG) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

10x Genomics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, 10x Genomics had 9 more articles in the media than Charles River Laboratories International. MarketBeat recorded 16 mentions for 10x Genomics and 7 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.07 beat 10x Genomics' score of 0.68 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics presently has a consensus price target of $44.00, indicating a potential downside of 39.46%. Charles River Laboratories International has a consensus price target of $265.69, indicating a potential downside of 2.91%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Charles River Laboratories International has a net margin of -5.96% compared to 10x Genomics' net margin of -12.18%. Charles River Laboratories International's return on equity of 15.75% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Charles River Laboratories International	-5.96%	15.75%	6.51%

10x Genomics has higher earnings, but lower revenue than Charles River Laboratories International. 10x Genomics is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	14.73	-$43.54M	-$0.59	N/A
Charles River Laboratories International	$4.02B	3.25	-$144.34M	-$4.85	N/A

Summary

Charles River Laboratories International beats 10x Genomics on 10 of the 16 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXG vs. The Competition

Export

Metric	10x Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.47B	$10.29B	$7.19B	$14.92B
Dividend Yield	N/A	1.47%	2.57%	11.71%
P/E Ratio	-123.18	67.95	274.09	25.35
Price / Sales	14.73	108.64	697.83	112.39
Price / Cash	N/A	26.23	77.71	51.48
Price / Book	11.65	5.46	10.37	6.25
Net Income	-$43.54M	$56.67B	$3.49B	$358.55M
7 Day Performance	8.01%	1.52%	-1.78%	-2.07%
1 Month Performance	29.58%	1.74%	-1.48%	-4.80%
1 Year Performance	453.54%	26.00%	18.20%	5.44%

10x Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXG 10x Genomics	1.3878 of 5 stars	$72.68 -2.3%	$44.00 -39.5%	+457.2%	$9.47B	$642.82M	N/A	1,178
PACB Pacific Biosciences of California	2.5329 of 5 stars	$1.35 flat	$1.83 +35.8%	+11.7%	$419.62M	$160.01M	N/A	730	News Coverage Gap Down
MTD Mettler-Toledo International	4.0786 of 5 stars	$1,344.87 0.0%	$1,445.31 +7.5%	+5.7%	$26.95B	$4.03B	30.27	18,100	Positive News
MEDP Medpace	2.4957 of 5 stars	$591.29 flat	$595.20 +0.7%	+25.0%	$16.50B	$2.53B	34.66	6,200	Positive News Analyst Forecast
RVTY Revvity	2.5693 of 5 stars	$130.24 +0.0%	$114.77 -11.9%	+66.6%	$14.53B	$2.86B	62.02	11,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXG) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Competitors

TXG vs. PACB, MTD, MEDP, RVTY, and CRL

How does 10x Genomics compare to Pacific Biosciences of California?

Summary

How does 10x Genomics compare to Mettler-Toledo International?

Summary

How does 10x Genomics compare to Medpace?

Summary

How does 10x Genomics compare to Revvity?

Summary

How does 10x Genomics compare to Charles River Laboratories International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Competitors

TXG vs. PACB, MTD, MEDP, RVTY, and CRL

How does 10x Genomics compare to Pacific Biosciences of California?

Does the media favor TXG or PACB?

Which has stronger earnings & valuation, TXG or PACB?

Which has more risk and volatility, TXG or PACB?

Do insiders & institutionals believe in TXG or PACB?

Is TXG or PACB more profitable?

Do analysts rate TXG or PACB?

Summary

How does 10x Genomics compare to Mettler-Toledo International?

Do insiders & institutionals believe in TXG or MTD?

Which has more risk and volatility, TXG or MTD?

Do analysts rate TXG or MTD?

Does the media favor TXG or MTD?

Which has stronger valuation and earnings, TXG or MTD?

Is TXG or MTD more profitable?

Summary

How does 10x Genomics compare to Medpace?

Which has higher valuation & earnings, TXG or MEDP?

Does the media prefer TXG or MEDP?

Do insiders and institutionals believe in TXG or MEDP?

Do analysts recommend TXG or MEDP?

Which has more volatility and risk, TXG or MEDP?

Is TXG or MEDP more profitable?

Summary

How does 10x Genomics compare to Revvity?

Is TXG or RVTY more profitable?

Does the media favor TXG or RVTY?

Do analysts recommend TXG or RVTY?

Which has more volatility and risk, TXG or RVTY?

Which has better valuation & earnings, TXG or RVTY?

Do insiders and institutionals hold more shares of TXG or RVTY?

Summary

How does 10x Genomics compare to Charles River Laboratories International?

Which has more risk & volatility, TXG or CRL?

Does the media prefer TXG or CRL?

Do analysts rate TXG or CRL?

Do insiders and institutionals have more ownership in TXG or CRL?

Is TXG or CRL more profitable?

Which has stronger earnings & valuation, TXG or CRL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools